Premium
Analysis of the MDM2 antagonist nutlin‐3 in human prostate cancer cells
Author(s) -
Logan Ian R.,
McNeill Hesta V.,
Cook Susan,
Lu Xiaohong,
Lunec John,
Robson Craig N.
Publication year - 2007
Publication title -
the prostate
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.295
H-Index - 123
eISSN - 1097-0045
pISSN - 0270-4137
DOI - 10.1002/pros.20568
Subject(s) - lncap , androgen receptor , prostate cancer , cancer research , mdm2 , cell growth , chromatin immunoprecipitation , apoptosis , cell cycle , biology , chromatin , prostate , cancer , medicine , gene expression , gene , biochemistry , promoter
BACKGROUND Small molecule MDM2 antagonists including nutlin‐3 have been shown to be effective against a range of cancer cell types and nutlin‐3 can inhibit growth of LNCaP xenografts. We compared the efficacy of nutlin‐3 in three prostate cancer cell types and provide an insight into the mechanism of nutlin‐3. METHODS Nutlin‐3 efficacy was measured using proliferation assays, cell cycle analysis, apoptosis assays, quantitative RT‐PCR, and immunoblotting. Chromatin immunoprecipitation (ChIP) assays were also performed. RESULTS Nutlin‐3 can specifically inhibit proliferation of LNCaP cells through cell cycle arrest and apoptosis. This coincides with increased levels of the p53‐responsive transcripts p21, PUMA, gadd45, and Mdm2 and recruitment of p53 to chromatin. Nutlin‐3 also reduces androgen receptor levels, resulting in altered receptor recruitment to chromatin. CONCLUSION Our study demonstrates that small molecule MDM2 antagonists might be useful in the treatment of human prostate cancers that retain functional p53 and androgen receptor signaling. Prostate 67: 900–906, 2007. © 2007 Wiley‐Liss, Inc.